

Appendix S1

ACKNOWLEDGEMENTS AND CONFLICT OF INTEREST

PSONET (www.psonet.eu) represents an international collaboration and is dependent on contributions from many members and advisors within the collaboration, who are gratefully acknowledged for their contribution. In particular, the authors would like to thank the collaboration of the following PSONET members: Francesco Cusano (Italy), Olivier Chosidow (France), Tony Ormerod (UK), Marcus Schmitz Egenolf (Sweden), Lidian Lecluse and Celine Busard (The Netherlands). All of the participating registries rely on contributions from many individuals who contribute to the AMC psoriasis registry, Australasian Psoriasis Registry, BADBIR, Biobadaderm, Clalit Health Services, DERMBIO, PSOBEST, PSOCARE, PsoReg and PsoBioTeq. The authors would like to acknowledge their vital ongoing support.

Funding sources: PSONET was supported by funding from the European Academy of Dermatology and Venereology (EADV) and the Italian Drug Agency (AIFA). The AMC psoriasis registry is funded by the Department of Dermatology of the Academic Medical Centre. The Australasian Psoriasis Registry was supported by unconditional funding from Epiderm, Abbott, Pfizer, Janssen-Cilag, Merck-Serono and MSD. Biobadaderm was supported by unconditional funding from the Academia Española de Dermatología y Venereología, Agencia Española de Medicamentos y Productos Sanitarios, Abbott, Schering, MSD, Wyeth, Pfizer and Janssen-Cilag. DERMBIO has received sponsoring from Abbott,

Janssen-Cilag, MSD and Pfizer. PSOBEST was supported by Abbott, MSD, Pfizer, Janssen-Cilag, Biogen Idec and Medac. None of the funders participated in the analysis or preparation or reviewed the manuscript.

Conflict of interest: PD-S received travel grants for congresses from Pfizer and Janssen. IG-D received congress grants from Pfizer, Janssen, and MSD. TND is a consultant and/or speaker for Abbott, Janssen-Cilag, LEO Pharma, MSD, Novo Nordisk and Pfizer. LN is a member of the scientific board of the PSOLAR registry, which is supported by Centocor. MA has received grants and/or honoraria as a consultant, speaker, and/or advisory board member from Abbvie, Almirall, Amgen, Astellas, Biogen, Celgene, Eli Lilly, Janssen, Leo, MSD, Merck-Serono, Mundipharma, Novartis, Pfizer, Pohl-Boskamp, UCB, and Xenoport. CB has received research support from Epiderm, Abbott, Pfizer, Janssen-Cilag, Merck-Serono and MSD. ED served as a consultant for AbbVie Laboratories, Amgen, Astellas, Celgene, Centocor Ortho Biotech Inc, Galderma, Glaxo, Janssen-Cilag, Leo Pharma, MSD, Novartis, and Pfizer Inc.; received honoraria from Abbott Laboratories, Amgen, Celgene, Janssen-Cilag Pty Ltd, Leo Pharma, MSD, Novartis, and Pfizer Inc; participated in speakers' bureaus for AbbVie Laboratories, Janssen Pharmaceuticals Inc, MSD, and Pfizer Inc.; and received grants from AbbVie Laboratories, Janssen Pharmaceuticals Inc., and Pfizer Inc. PIS is principal investigator in many pharmaceutical initiated trials in her department, has received departmental research support from MSD and attended advisory board meetings for Leo Pharma and Janssen. ADC has received consultation fees from MSD and Abbott. The other authors declare no conflicts of interest.




Fig. S1. Forest plot showing the overall result in psoriasis characteristics of patients with substantial heterogeneity ($I^2 > 60\%$) in both biologic and control group among different registries. The main differences are found between biologic and conventional treatment groups of psoriasis in: (a) age at entry, (b) age at diagnosis, (c) Dermatology Quality of Life Index (DLQI), (d) Psoriasis Area Severity Index (PASI), (e) body surface area affected (BSA) and the odds ratio (OR) of biologic use compared with conventional treatment among (f) male patients, (g) patients with psoriatic arthritis, (h) patients with psoriasis different from chronic plaque psoriasis, and (i) with nail disease.

Table SI. Description of participating registries^a

Registry name, country	AMC psoriasis registry, Netherlands	Australasian Psoriasis Registry, Australia	Biobadaderm, Spain	Clalit Health Service, Israel	Dermbio, Denmark	PsoBest, Germany	Psocare, Italy
Registry started, year ^b	2008	2008	2008	2007	2007	2008	2005
Centres participating in registry ^a , n	1	10	13	3,500	5 hospital, 10 private	530 hospital and private	164
Patients registered on biologics	194	475	793	554	1083	378	6,191
Patients registered on classic systemic drugs	0	29	632	3,204	161	1,167	5,371
Population of country (millions) ^a	16	22	46	7.7	6	81	70
Estimated % of the population sampled by each registry ^{a*}	0.05%	0.05%	<10%	100%	>90%	10%	80%

*Percentage is calculated with all patients included in each registry.

^aAdapted from from García-Doval et al (1). The Academic Medical Center (AMC) psoriasis registry does not have a control group receiving classic therapy. Registry enrolment of patients receiving biologics was compulsory in Denmark and Italy. Clalit Health Services data were abstracted from computerized patient records of this health maintenance organization. In the Australasian Psoriasis Registry, with the exception of infliximab, is there no requirement for attempting previous classic systemic therapy. Dermbio registry added retrospectively available data for biologic treatments that had been initiated before the launch of the Danish registry. ^bData obtained from Ormerod et al. (3).

Table SII. Demographic baseline characteristics of patients with psoriasis in both biologic and control group among different registries

Demographics	Biologics		Classic drugs	
	Patients <i>n</i>	Mean (95% CI)	Patients <i>n</i>	Mean (95% CI)
Mean age				
AMC psoriasis registry, The Netherlands	194	50.6 (48.8–52.4)	NA	NA
Australian Psoriasis	475	49.8 (48.6–51.0)	29	50.7 (45.2–56.2)
Biobadaderm, Spain	793	43.9 (42.9–44.8)	632	45.9 (44.8–47.12)
Clalit Health Service, Israel	554	52.3 (51.1–53.5)	3,204	53.0 (52.4–53.6)
Dermbio, Denmark	1,083	45.3 (44.5–46.1)	161	43.2 (41.2–45.3)
PsoBest, Germany	378	48.4 (47.0– 49.8)	1,167	46.9 (46.1–47.8)
Psocare, Italy	6,191	47.8 (47.5–48.2)	5,371	49.1 (48.7–49.5)
Percentage of males				
AMC psoriasis registry, The Netherlands	120	61.9 (55.0–68.7)	NA	NA
Australian Psoriasis	319	66.9 (62.7–71.1)	19	65.5 (48.2–82.8)
Biobadaderm, Spain	502	63.3 (59.9–66.7)	369	58.4 (54.5–62.2)
Clalit Health Service, Israel	286	51.6 (47.5–55.8)	1,811	56.5 (54.8–58.2)
Dermbio, Denmark	686	63.3 (60.5–66.2)	93	57.8 (50.1–65.4)
PsoBest, Germany	235	61.8 (57.0–66.7)	1,811	57.3 (54.4–60.1)
Psocare, Italy	4,173	67.4 (66.2–68.6)	3,535	65.8 (64.5–67.1)
Percentage of current drinkers				
Australian Psoriasis	227	74.2 (69.3–79.1)	7	63.6 (35.2–92.1)
Biobadaderm, Spain	176	28.8 (25.2–32.4)	153	31.1 (27.0–35.2)
PsoBest, Germany	19	5.0 (2.8–7.2)	45	3.8 (2.7–4.9)
Psocare, Italy	2,160	34.9 (33.7–36.1)	1,962	36.5 (35.2–37.8)
Percentage of current smokers				
Australian Psoriasis	30	10.5 (7.0–14.1)	1	33.3 (–20.0–86.7)
Biobadaderm, Spain	232	35.7 (32.1–39.4)	228	41.8 (37.6–45.9)
Clalit Health Service, Israel	137	24.7 (21.1–28.3)	862	27.2 (25.7–28.8)
PsoBest, Germany	146	38.4 (33.5–43.3)	507	43.3 (40.5–46.2)
Psocare, Italy	2,357	38.1 (36.9–39.3)	2,101	39.1 (37.8–40.4)
Mean body mass index				
AM, psoriasis registry, The Netherlands	167	28.7 (27.7–29.7)	NA	NA
Australian Psoriasis	367	29.2 (28.4–30.0)	24	30.0 (27.4–32.6)
Biobadaderm, Spain	626	27.9 (27.5–28.4)	537	27.6 (27.2–28.0)
Clalit Health Service, Israel	548	30.5 (28.7–32.3)	3,141	29.1 (28.6–29.6)
Dermbio, Denmark	404	28.9 (28.1–29.7)	50	27.4 (25.9–28.9)
PsoBest, Germany	379	28.3 (27.8–28.8)	1,163	27.9 (27.5–28.3)
Psocare, Italy	5,869	27.2 (27.1–27.3)	5,138	26.8 (26.7–26.9)

CI: confidence interval; NA: not available; AMC: Academic Medical Center.

Table SIII. Disease-related variables of patients with psoriasis in both biologic and control group among different registries

Characteristics of psoriasis	Biologics		Conventional treatment	
	Patients <i>n</i>	Mean (95% CI)	Patients <i>n</i>	Mean (95% CI)
Mean age at diagnosis				
AMC psoriasis registry, The Netherlands	189	25.1 (23.2–27.1)	NA	NA
Australian Psoriasis	337	26.0 (24.5–27.5)	20	27.0 (20.0–34.0)
Biobadaderm, Spain	786	25.3 (24.3–26.3)	629	29.8 (28.5–31.1)
Clalit Health Service, Israel	554	49.8 (48.6–51.1)	3,204	51.0 (50.5–51.6)
Dermbio, Denmark	901	27.2 (26.2–28.2)	133	26.3 (23.7–28.9)
PsoBest, Germany	349	28.0 (26.5–29.5)	1,100	29.0 (28.0–30.0)
Psocare, Italy	6,006	30.0 (29.6–30.4)	5,215	34.0 (33.5–34.5)
Percentage with psoriasis different from plaque psoriasis				
Australian Psoriasis	22	5.6 (3.3–7.9)	2	6.9 (–2.3–16.1)
Biobadaderm, Spain	41	5.2 (3.6–6.7)	62	9.8 (7.5–12.1)
Dermbio, Denmark	109	10.1 (8.3–11.9)	8	5.0 (1.6–8.3)
PsoBest, Germany	26	6.8 (4.3–9.4)	107	9.1 (7.5–10.8)
Psocare, Italy	829	13.4 (12.5–14.2)	953	17.7 (16.7–18.8)
Percentage with arthritis				
AMC psoriasis registry, The Netherlands	50	27.6 (21.1–34.1)	NA	NA
Australian Psoriasis	190	39.8 (35.4–44.2)	7	24.1 (8.6–39.7)
Biobadaderm, Spain	133	16.8 (14.2–19.4)	50	7.9 (5.8–10.0)
Dermbio, Denmark	337	31.1 (28.4–33.9)	56	34.8 (27.4–42.1)
PsoBest, Germany	150	39.5 (34.6–44.4)	138	11.8 (9.9–13.6)
Psocare, Italy	2,170	35.1 (33.9–36.2)	729	13.6 (12.7–14.5)
Percentage with nail disease				
Australian Psoriasis	71	14.9 (11.7–18.1)	5	18.5 (3.9–33.2)
Dermbio, Denmark	115	10.6 (8.8–12.5)	20	12.4 (7.3–17.5)
PsoBest, Germany		64.2 (59.4–69.0)		51.0 (48.2–53.9)
Psocare, Italy	2,591	41.9 (40.6–43.1)	1,785	33.2 (32.0–34.5)
Mean Psoriasis Area and Severity Index				
AMC psoriasis registry, The Netherlands	173	14.5 (13.5–15.5)	NA	NA
Australian Psoriasis	423	30.8 (29.0–32.6)	11	25.5 (17.2–33.7)
Biobadaderm, Spain	613	16.5 (15.7–17.3)	478	10.3 (9.7–10.9)
Dermbio, Denmark	848	10.8 (10.2–11.4)	134	12.4 (10.9–13.8)
PsoBest, Germany	370	15.3 (14.3–16.4)	1,140	14.7 (14.2–15.2)
Psocare, Italy	4,505	18.5 (18.2–18.9)	3,977	16.4 (16.1–16.7)
Mean body surface area				
AMC psoriasis registry, The Netherlands	167	18.1 (15.8–20.4)	NA	NA
PsoBest, Germany	374	26.9 (24.7–29.1)	1,126	24.2 (23.1–25.4)
Mean Dermatology Life Quality Index				
Australian Psoriasis	99	17.2 (15.9–18.6)	2	19.5 (4.8–34.2)
Dermbio, Denmark	595	10.2 (9.6–10.8)	87	12.4 (10.9–13.9)
PsoBest, Germany	370	12.5 (11.7–13.2)	1,146	11.0 (10.6–11.4)

CI: confidence interval; NA: not available; AMC: Academic Medical Center.